Analyzing Nanosphere (NSPH) & Hologic (HOLX)
Nanosphere (NASDAQ: NSPH) and Hologic (NASDAQ:HOLX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.
Risk and Volatility
Nanosphere has a beta of 3.22, meaning that its share price is 222% more volatile than the S&P 500. Comparatively, Hologic has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
Institutional & Insider Ownership
96.4% of Hologic shares are owned by institutional investors. 0.8% of Hologic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares Nanosphere and Hologic’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Nanosphere and Hologic’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Hologic||$2.98 billion||3.55||$1.01 billion||$2.68||14.07|
Hologic has higher revenue and earnings than Nanosphere.
This is a breakdown of recent ratings and price targets for Nanosphere and Hologic, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Hologic has a consensus target price of $48.62, indicating a potential upside of 28.88%. Given Hologic’s higher possible upside, analysts clearly believe Hologic is more favorable than Nanosphere.
Hologic beats Nanosphere on 8 of the 9 factors compared between the two stocks.
Nanosphere Company Profile
Nanosphere, Inc. is engaged in developing, manufacturing and marketing an advanced molecular diagnostics platform, the Verigene System, which enables genomic and protein testing on a single platform. The Verigene System includes a molecular diagnostics workstation that is a single use consumable for testing. The Verigene System consists of a microfluidics processor, a touchscreen reader and disposable test cartridges. The Company is focused on the infectious disease diagnostics market. Its Infectious Disease Assays include Respiratory Virus with Sub-Typing (RV+); Respiratory Pathogens/Expanded Panel (RP Flex); Bloodstream Infection (BSI) Panels, which include Blood Culture – Gram Positive (BC-GP), Blood Culture – Gram Negative (BC-GN) and Blood Culture – Yeast (BC-Y); C. difficile (CDF), and Enteric Panel (EP). Its Human Pharmacogenetic Assays include Hypercoagulation (FV, FII, MTHFR Panel) and CYP2C19 Genetic Variance. It is focused on the infectious disease diagnostics market.
Hologic Company Profile
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.
Receive News & Ratings for Nanosphere Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanosphere Inc. and related companies with MarketBeat.com's FREE daily email newsletter.